Abbott partners with Novo Nordisk India to launch Extensior®, broadening access to Semaglutide (Ozempic®) for advanced diabetes management
<ul class='hocal_short_desc'><li> The collaboration brings together Novo Nordisk’s global GLP-1 leadership and Abbott’s strong India footprint, helping more people with type 2 diabetes benefit from modern, evidence-based diabetes therapies</li><li> Under the agreement, Abbott will commercialize Novo Nordisk’s semaglutide (Ozempic®) under the brand name Extensior®</li><li> Extensior® offers powerful HbA1c reduction, weight-loss benefits, and proven risk reduction of cardiovascular and kidney events in people with type 2 diabetes</li></ul>
